In this position, Dr Bedigian will take the lead and be responsible for all medical aspects of Isis’s clinical development programs. Dr Bedigian comes to Isis from Novartis Pharmaceuticals where he was the global head of the cardiovascular assessment group.
Dr Bedigian received his medical degree from New York Medical College and completed his residency in internal medicine at Emory University.
Stanley Crooke, chairman and CEO of Isis, said: “Martin’s training and expertise across all of the therapeutic areas of our pipeline will nicely complement our expanding drug development pipeline.”